体细胞与胚系突变对系统性肥大细胞增多症结局的影响
该研究对34例伴多系KIT D816V突变的系统性肥大细胞增多症患者进行靶向测序(410个基因)和全基因组测序,发现除KIT D816V外无共同突变,但鉴定出67个涉及39个基因的非同义变异,其中半数为体细胞突变(多为多系),半数为胚系变异。≥1个累及非KIT D816V基因的多系体细胞突变、≥3个胚系变异以及S/A/R/E基因的多系突变与更差的患者结局相关,其中多系突变(尤其涉及S/A/R/E基因)是唯一独立预测无进展生存期和总生存期的因素。
要点
- 在34例伴多系KIT D816V突变的系统性肥大细胞增多症患者中,靶向测序鉴定出67个涉及39个基因的非同义变异,半数为体细胞突变,半数为胚系变异。
- ≥1个累及非KIT D816V基因的多系体细胞突变、≥3个胚系变异以及S/A/R/E基因的多系突变与更差结局相关。
- 多系突变(尤其涉及S/A/R/E基因)是唯一独立预测无进展生存期和总生存期的因素。
核心结论
- 在伴多系KIT D816V突变的系统性肥大细胞增多症患者中,多系突变(尤其涉及S/A/R/E基因)是唯一独立预测无进展生存期和总生存期的因素。
研究设计与样本
- 研究纳入34例伴多系KIT D816V突变的系统性肥大细胞增多症患者,对其中12例非晚期和8例晚期患者的纯化骨髓细胞及毛发DNA进行410个基因的靶向测序,并对4例进行全基因组测序,另在14例晚期患者中进一步检测体细胞突变。
主要发现
- 全基因组测序分析中除KIT D816V外未发现其他共同突变。
- 靶向下一代测序鉴定出67个涉及39个基因的非同义遗传变异,其中半数为体细胞突变(大多为多系),半数为胚系变异。
- ≥1个累及非KIT D816V基因的多系体细胞突变、≥3个胚系变异以及S/A/R/E基因(SRSF2、ASXL1、RUNX1和/或EZH2)的多系突变,连同皮肤病变、脾肿大、血小板减少、低血红蛋白水平以及碱性磷酸酶和β2微球蛋白血清水平升高,均与更差的患者结局相关。
- 多系突变(尤其涉及S/A/R/E基因)是唯一独立预测无进展生存期和总生存期的因素。
关键数值与推荐
- 多系突变(尤其涉及S/A/R/E基因)是唯一独立预测无进展生存期和总生存期的因素。
- ≥1个累及非KIT D816V基因的多系体细胞突变、≥3个胚系变异以及S/A/R/E基因的多系突变与更差的患者结局相关。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Systemic mastocytosis (SM) is a highly heterogeneous disease with indolent and aggressive forms, with the mechanisms leading to malignant transformation still remaining to be elucidated. Here, we investigated the presence and frequency of genetic variants in 34 SM patients with multilineal KIT D816V mutations. Initial screening was performed by targeted sequencing of 410 genes in DNA extracted from purified bone marrow cells and hair from 12 patients with nonadvanced SM and 8 patients with advanced SM, followed by whole-genome sequencing (WGS) in 4 cases. Somatic mutations were further investigated in another 14 patients with advanced SM. Despite the fact that no common mutation other than KIT D816V was found in WGS analyses, targeted next-generation sequencing identified 67 nonsynonymous genetic variants involving 39 genes. Half of the mutations were somatic (mostly multilineal), whereas the other half were germline variants. The presence of ≥1 multilineal somatic mutation involving genes other than KIT D816V, ≥3 germline variants, and ≥1 multilineal mutation in the SRSF2, ASXL1, RUNX1, and/or EZH2 genes (S/A/R/E genes), in addition to skin lesions, splenomegaly, thrombocytopenia, low hemoglobin levels, and increased alkaline phosphatase and β2-microglobulin serum levels, were associated with a poorer patient outcome. However, the presence of ≥1 multilineal mutation, particularly involving S/A/R/E genes, was the only independent predictor for progression-free survival and overall survival in our cohort.
引用
- Muñoz-González JI, Jara-Acevedo M, Alvarez-Twose I, et al. Impact of somatic and germline mutations on the outcome of systemic mastocytosis. Blood Adv. 2018. PMID: 30373888. doi:10.1182/bloodadvances.2018020628
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。